Clinical trials: Neoplasm Recurrence
Sarcoma
Safety and Efficacy Study Using Rexin-G for Sarcoma
Rexin-G is a tumor-targeted (pathotropic or disease-seeking) nanoparticle that when injected intravenously, seeks out and accumulates in cancerous lesions, thus enhancing local drug concentration within tumors.
- Trial name
- NCT00505713
- Testing
- Rexin-G
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Epeius Biotechnologies
Solid Tumors, Lymphoma
Study of AR-12 (2-Amino-N-[4-[5-(2 Phenanthrenyl)-3-(Trifluoromethyl)-1H-pyrazol-1-yl] Phenyl]-Acetamide) in Adult Patients With Advanced or Recurrent Solid Tumors or Lymphoma
The primary objective of this study in adults with advanced or recurrent solid tumors or lymphoma is to evaluate the safety and tolerability of AR-12 by describing dose-limiting toxicities (DLTs), and thereby establishing the…
- Trial name
- NCT00978523
- Testing
- AR-12: (2-Amino-N-[4-[5-(2 phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-acetamide)
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 35 people
- Sponsor
- Arno Therapeutics
Ovarian Neoplasms
Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)
This study will assess the efficacy and safety of pembrolizumab (MK-3475) monotherapy in female participants with recurrent ovarian cancer (ROC) who have received up to 5 prior lines of treatment including platinum-based…
- Trial name
- NCT02674061
- Testing
- Pembrolizumab
- Volunteers
- 376 people
- Sponsor
- Merck Sharp & Dohme LLC
Solid Organ Tumors
A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study
The purpose of this research study is to collect information from patient's medical records that had a test called ChemoFx® ordered and to understand how doctors may have used the results of the ChemoFx® to treat patients with…
- Trial name
- NCT01271959
- Where
- 25 sites in United States
- Volunteers
- 167 people
- Sponsor
- Precision Therapeutics
Migraine Disorders
Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines
The purpose of the study is to investigate if the use of gammaCore Sapphire™ device reduces the number of migraines preventatively.
- Trial name
- NCT03716505
- Testing
- gammaCore Sapphire active
- Where
- 30 sites in United States
- Volunteers
- 231 people
- Sponsor
- ElectroCore INC
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
This study is to determine the response to acalabrutinib in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- Trial name
- NCT02337829
- Testing
- Acalabrutinib (Arm A), Acalabrutinib (Arm B)
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Acerta Pharma BV
Carcinoma, Non-small-cell Lung
A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)
This is a Phase I/IIa study to evaluate safety and efficacy of dalotuzumab (MK-0646) in combination with erlotinib in participants with recurrent Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT00654420
- Testing
- Dalotuzumab, Erlotinib
- Volunteers
- 95 people
- Sponsor
- Merck Sharp & Dohme LLC
Pleural Effusion
Investigation Into the Automated Drainage of Recurrent Effusions From the Pleural Space in Thoracic Malignancy.
This is a research study examining the safety of a new, automated pump for the drainage of fluid in the chest cavity which is caused by cancer (also known as malignant pleural effusion, or MPE).
- Trial name
- ADEPT (NCT01952327)
- Testing
- The pleurapump system
- Where
- 2 sites in France, United Kingdom
- Volunteers
- 2 people
- Sponsor
- Sequana Medical N.V.
Carcinoma, Hepatocellular
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
To evaluate efficacy and safety of sorafenib versus placebo in the adjuvant treatment of Hepatocellular Carcinoma (HCC) after potentially curative treatment (surgical resection or local ablation).
- Trial name
- STORM (NCT00692770)
- Testing
- Nexavar (Sorafenib, BAY43-9006)
- Where
- 199 sites in United States, Argentina and 26 more
- Volunteers
- 1,114 people
- Sponsor
- Bayer
Glioblastoma, Glioma
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
This open-label, multicenter, Phase I, dose-escalating study will evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of GDC-0084 in patients with progressive or recurrent high-grade glioma.
- Trial name
- NCT01547546
- Testing
- GDC-0084
- Where
- 5 sites in United States, Spain
- Volunteers
- 29 people
- Sponsor
- Genentech, Inc.
Solid Tumors
Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors
The purpose of this study is to determine the tolerability of ME-344, find the maximum tolerated dose, and the safety profile in patients with refractory solid tumors.
- Trial name
- ME-344-001 (NCT01544322)
- Testing
- ME-344
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- MEI Pharma, Inc.
Breast Cancer, Breast Carcinoma
Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
The goal of this clinical research study is to learn if the study drug, alisertib (MLN8237), in combination with chemotherapy (paclitaxel), can shrink or slow tumor growth in women with hormone receptor (HR)-positive, human…
- Conditions
- Breast Cancer, Breast Carcinoma, Breast Tumors, Malignant Neoplasm of Breast
- Trial name
- NCT02187991
- Testing
- Paclitaxel, Alisertib
- Where
- United States
- Volunteers
- 169 people
- Sponsor
- US Oncology Research
Lymphoma, Non-Hodgkin, Lymphoma, T-Cell
Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL
Phase I clinical study of multicenter, single-arm, open, non-randomized evaluation of recombinant humanized anti-CD52 monoclonal antibody in the NHL and T-PLL
- Trial name
- NCT05557903
- Testing
- Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Lanzhou Institute of Biological Products Co., Ltd
Lymphoma
Liposomal Vincristine in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal vincristine in treating patients who have…
- Trial name
- NCT00006383
- Testing
- liposomal vincristine sulfate
- Where
- 9 sites in United States, Canada
- Sponsor
- Inex Pharmaceuticals
Leukemia
CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CMA-676 in treating older patients who have acute…
- Trial name
- NCT00003673
- Testing
- chemotherapy, gemtuzumab ozogamicin
- Where
- 10 sites in United States
- Volunteers
- 55 people
- Sponsor
- Pfizer
Non-Hodgkin's Lymphoma
A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199
This is an open-label multicenter, study to assess the pharmacokinetic interaction of ketoconazole with ABT-199 in up to 12 subjects with relapsed or refractory non-Hodgkin's lymphoma.
- Trial name
- NCT01969669
- Testing
- ABT-199, Ketoconazole
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- AbbVie
Acute Lymphoblastic Leukemia
Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
The purpose of this study is to determine the dose of the bispecific T cell engager blinatumomab (MT103) in pediatric and adolescent patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and to assess whether this…
- Trial name
- NCT01471782
- Testing
- Blinatumomab
- Where
- 30 sites in United States, Austria and 5 more
- Volunteers
- 93 people
- Sponsor
- Amgen Research (Munich) GmbH
Glaucoma, Pterygium
Ologen (OculusGen)-Glaucoma and Pterygium Historical Control Study in China Beijing Hospital
The purpose of this study is to determine whether the OculusGen Collagen Matrix is effective and safe to implant as an aid of glaucoma and pterygium surgeries.
- Trial name
- NCT00320762
- Testing
- OculusGen Biodegradable Collagen Matrix Implant
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Pro Top & Mediking Company Limited
Recurrent Hepatocellular Carcinoma
A Study of LioCyx in Patient With Recurrent HBV-related HCC Post Liver Transplantation
Hepatocellular carcinoma (HCC) represent approximately 70-85% of liver cancer, in which Hepatitis B virus (HBV) is the major etiologic agent accounting for at least 80% of HCC in Asian countries.
- Trial name
- NCT03634683
- Testing
- LioCyx
- Where
- 3 sites in China, Singapore
- Sponsor
- Lion TCR Pte. Ltd.
Non-small Cell Lung Cancer (NSCLC)
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with carboplatin and paclitaxel in the treatment of chemonaive subjects with recurrent or advanced non-squamous NSCLC
- Trial name
- NCT00850577
- Testing
- Paclitaxel, Carboplatin, CT-322
- Where
- 55 sites in United States, Brazil and 6 more
- Volunteers
- 255 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.